First Squawk(@FirstSquawk):AMGEN SAYS IMDELLTRA PLUS DURVALUMAB EXTENDS MEDIAN OVERALL SURVIVAL TO 21.1 MONTHS VERSUS 12.7 MONTHS WITH DURVALUMAB ALONE, WITH THE SAFETY PROFILE CONSISTENT WITH THE KNOWN PROFILES OF THE INDIVIDUAL MEDICINES, AND GRADE 3 OR HIGHER ADVERSE EVENTS OCCURRING IN 20.9% WITH IMDELLTRA PLUS IMFINZI VERSUS 10.8% WITH IMFINZI ALONE

First Squawk

@FirstSquawk

Firstsquawk Is a Global Financial (News) Squawk Service Specialising In Financial Markets, Macro, Geopolitics,politics

Joined July 2015

252 Following 578.7K Followers

First Squawk@FirstSquawk

2026.10.24 14:38

AMGEN SAYS IMDELLTRA PLUS DURVALUMAB EXTENDS MEDIAN OVERALL SURVIVAL TO 21.1 MONTHS VERSUS 12.7 MONTHS WITH DURVALUMAB ALONE, WITH THE SAFETY PROFILE CONSISTENT WITH THE KNOWN PROFILES OF THE INDIVIDUAL MEDICINES, AND GRADE 3 OR HIGHER ADVERSE EVENTS OCCURRING IN 20.9% WITH IMDELLTRA PLUS IMFINZI VERSUS 10.8% WITH IMFINZI ALONE